Study findings published in the New England Journal of Medicine, issued by the American Heart Association (AMA), the number of US adults eligible for statin therapy would increase by 12.8 million. This will be a boon for the pharmaceutical industry but some cardiologists including Steven Nissen at the Cleveland Clinic, the issue warrants closer examination as the risks of wholesale prescription of these drugs is unknown.
The findings indicated that the number of adults either receiving or eligible to receive statin drugs would rise to 56 million. The year by year profits for sale of statins would skyrocket.
In addition, the increase seen among older adults without cardiovascular disease.
Jeff Newman represents whistleblowers.
